News Releases

Date Title and Summary Additional Formats
Jun 10, 2021 Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases
Collaboration plans for developing biological therapies potentially targeting multiple ophthalmic diseases utilizing APT’s PhageBank™ technology Oyster Point Pharma plans to discuss the potential for bacteriophage in the treatment of ophthalmic diseases at the upcoming Oyster Point Pharma Analyst
Jun 03, 2021 Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases
Introduction of proprietary ETF™ Gene Therapy and first gene candidate, nerve growth factor (NGF), to target Stages 2 and 3 Neurotrophic Keratopathy (NK) Preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an
May 06, 2021 Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights
PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021 Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4 2021, if approved by the FDA OLYMPIA Phase 2 Study on Track, with Planned Enrollment of the First Patient in 1H 2021 Continued Organizational Advancement
May 01, 2021 Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data
Apr 30, 2021 Oyster Point Pharma to Report First Quarter 2021 Financial Results on May 6, 2021
Conference Call and Webcast Scheduled for May 6, 2021, 4:30 p.m. Eastern Time PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class
Apr 05, 2021 Oyster Point Pharma Announces New Appointment to Board of Directors
George Eliades joins the Board of Directors PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular
Mar 02, 2021 Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
Prescription Drug User Fee Act ( PDUFA) target action date is October 17, 2021 U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss this application Planned U.S. launch of OC-01 (varenicline) nasal spray in fourth quarter of
Feb 25, 2021 Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference
PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the
Feb 18, 2021 Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
OC-01 (Varenicline) Nasal Spray New Drug Application (NDA) Submitted to the U.S. Food and Drug Administration (FDA) for the Treatment of Signs and Symptoms of Dry Eye Disease on December 17, 2020 Phase 2 Clinical Trial Protocol of OC-01 (Varenicline) Nasal Spray in Patients with Neurotrophic
Feb 12, 2021 Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021
Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET PRINCETON, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class
Displaying 11 - 20 of 20